Boehringer Ingelheim registers Phase 3 VERANDA-IIM trial of nerandomilast in myositis
The trial, not yet recruiting, will test nerandomilast against placebo in adults with active idiopathic inflammatory myopathies over 52 weeks.
Boehringer Ingelheim registered one new trial this week.
- A Phase 3 study called "VERANDA™-IIM" (NCT07789015) will evaluate nerandomilast oral therapy added to standard background therapy over 52 weeks in adult participants with active idiopathic inflammatory myopathies1. The trial is listed as not yet recruiting, with an estimated enrollment of 270 participants1 and a primary outcome of total improvement score (TIS) at Week 521.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.